Eteplirsen for the treatment of Duchenne muscular dystrophy
Jerry R. Mendell(Nationwide Children's Hospital), Zarife Sahenk(The Ohio State University), Marco Corridore(Nationwide Children's Hospital), Janaiah Kota(Ultragenyx Pharmaceutical (United States)), Peter Sazani(Sarepta Therapeutics (United States)), Hugh D. Allen(Texas Children's Hospital), Lindsay N. Alfano(Nationwide Children's Hospital), Jay Saoud(Sarepta Therapeutics (United States)), Kevin M. Flanigan(Nationwide Children's Hospital), Christopher M. Walker(University of Kansas Medical Center), Sarah Lewis(Nationwide Children's Hospital), John R. Kean(Nationwide Children's Hospital), Kim Shontz(Nationwide Children's Hospital), A.M. Gomez(Nationwide Children's Hospital), Vinod Malik(Nationwide Children's Hospital), Linda Lowes(Nationwide Children's Hospital), Edward M. Kaye(Sarepta Therapeutics (United States)), Loren Bird(Nationwide Children's Hospital), Kathleen R. Melia(Sarepta Therapeutics (United States)), Chris Shilling(Nationwide Children's Hospital), Louise R. Rodino‐Klapac(Sarepta Therapeutics (United States)), Kandice Roush(Nationwide Children's Hospital)
Cited by 793
Related Papers
CD8 <sup>+</sup> Lymphocytes Can Control HIV Infection in Vitro by Suppressing Virus Replication
|Science|1986|993
Evidence‐based path to newborn screening for duchenne muscular dystrophy
|Annals of Neurology|2012|816
Dystrophin Immunity in Duchenne's Muscular Dystrophy
|New England Journal of Medicine|2010|655
Clinical trial in duchenne dystrophy. I. The design of the protocol
|Muscle & Nerve|1981|563
Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy
|New England Journal of Medicine|1995|522